Director, Global Health Economics Lead, Oncology Business Unit

Job Description About the role:

As a member of Takeda Oncology, your work will contribute to our bold, inspiring vision:
We aspire to cure cancer. Here, you'll build a career grounded in purpose and be empowered to deliver your best. As part of the Global Health Economics team, you will report to the Head of Global Health Economics and US HEOR.

• Drive and realize value demonstration strategies for Takeda’s global oncology portfolio, achieving rapid, broad patient access and delivering differentiated, evidence-based pricing through best-in‑class health technology assessment (HTA; including the EU Joint Clinical Assessment [JCA]) and payer decision outcomes. Lead cross‑functional integration and impact, resulting in accelerated market access, measurable commercial performance, and sustainable advantage across various assets and indications worldwide.

• Lead the strategic development, execution, and continuous optimization of global health economics (HE) plans, reimbursement strategy, and evidence communication. Build and deploy best‑practice tools and training to maximize adoption and impact of global HE deliverables across all regions.

• Mobilize and align cross‑functional and cross‑regional stakeholders at all enterprise levels, including R&D, Market Access, and local operating companies (LOC), to ensure seamless integration of evidence requirements and accelerate value realization for patients and payers.

• Co‑lead the vision, development, and adaptive evolution of enterprise‑level frameworks (e.g., Integrated Evidence Generation Plans [EGPs]), ensuring that all evidence and access strategies are fully aligned with evolving payer, HTA, and policy needs globally.

• Pioneer and implement innovative digital, data science, and AI‑driven health economics and outcomes research (HEOR) approaches, actively shaping Takeda’s future market access strategy. Influence enterprise‑level decision‑making and mentor emerging leaders through formal educational and strategic thought leadership programs.

• Advance Takeda’s global reputation and influence by proactively shaping thought leadership at international and industry forums, policy discussions, and leading scientific consortia—building strong partnerships with HTA, payer, academic and clinical stakeholders, and elevating Takeda’s position as a recognized leader in HE and value demonstration.

Global Value Proposition:

• Drive and deliver differentiated, evidence‑based global HE value propositions resulting in best‑in‑class HTA/payer decisions, accelerated market access, and sustainable competitive advantage across the oncology portfolio. Anticipate and capitalize on emerging payer and societal needs.
• Direct and oversee the co‑development with Global Pricing, Value & Access (PVA) and cross‑functional leaders to build compelling, evolving value narratives that impact payer decisions and drive optimal patient access worldwide.
• Drive strategic identification and prioritization of high‑value opportunities—including new indications, lifecycle extensions, and innovative contracting models—across the portfolio.

Evidence Generation:

• Provide enterprise‑wide vision and impactful leadership in evidence generation to secure HTA, payer, and market access objectives, integrating payer and real‑world data needs across global, regional, and local programs.
• Pioneer new approaches, including digital, data science, and AI, to transform evidence generation and proactively shape Takeda’s response to dynamic global value trends.
• Review recommendations for advanced evidence needs (e.g., RWE, patient‑centered outcomes), ensuring that internal and external partners are aligned to address emerging payer trends and requirements.
• Lead the incorporation of innovative and payer‑relevant endpoints in clinical development strategies and ensure robust HTA (including JCA) readiness.

HE and Value & Access Tools:

• Set enterprise‑wide benchmarks for scientific rigor in HEOR studies; ensure continuous innovation, external credibility, and differentiation with HTA bodies and payers.
• Drive the implementation of global HE strategies and tools (Value Platforms, Dossiers, value‑based contract (VBC)…